{
    "data": [
        {
            "title": "A Look At NIBE Industrier (OM:NIBE B) Valuation After Germany‚Äôs Shifting Heat Pump Policies",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Germany‚Äôs 49% year-on-year jump in January heat pump subsidy applications, alongside a softer heating law that reduces renewable requirements, puts NIBE Industrier (OM:NIBE B) in a mixed position within a key market.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for NIBE Industrier.</a></p> <p>At a share price of SEK37.07, NIBE‚Äôs recent 7.57% 1 month share price return contrasts with a 7.25% decline in 1 year total shareholder return and a 65.32% drop over three years. This suggests momentum has picked up recently, while longer term holders remain under pressure.</p> <p>If Germany‚Äôs heat pump policy shift has you thinking about where future infrastructure spending could land, it may be worth checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as a starting list of ideas.</p> <p>With NIBE trading at SEK37.07 and sitting on a 20% implied discount to one set of valuation estimates, the key question is whether recent setbacks have already reset expectations or whether the market is still pricing in ambitious future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 9.1% Undervalued</h2> <p>With NIBE Industrier‚Äôs last close at SEK37.07 against a narrative fair value of SEK40.77, the current pricing sits below what the narrative model suggests, according to Unike.</p> <blockquote> <p><em>Regulatory Support for Heat Pumps: The EU‚Äôs decarbonization plan aims for 60 million heat pumps installed by 2030, creating strong demand.</em></p> <p><em>Technological Advancements: R&amp;D in next-generation heat pumps and smart energy solutions could boost efficiency and margins.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/v3mri2m5-nibe-industrier-will-ride-the-green-energy-subsidy-wave\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious how one narrative gets to that higher fair value. It leans heavily on steady expansion, firmer margins, and a future earnings multiple usually tied to premium growth stories. Want to see which specific growth and profitability assumptions sit under that headline number.</p> <p><strong>Result: Fair Value of SEK40.77 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/v3mri2m5-nibe-industrier-will-ride-the-green-energy-subsidy-wave\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this depends on continued subsidy support and resilient end demand. Any cutbacks in incentives or a broader economic slowdown could undermine that optimistic setup.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this NIBE Industrier narrative.</a></p> <h2>Next Steps</h2> <p>Given all this, are you feeling cautious or curious about where NIBE really stands? Do not wait for someone else‚Äôs verdict. Weigh up the story yourself by checking the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> and see how the full risk reward picture lines up with your own expectations.</p> <h2>Looking for more investment ideas?</h2> <p>If this story has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused idea lists built from our stock screener tools.</p> <ul> <li>Start with quality by scanning companies that pass balance sheet and fundamentals checks using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/global\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (370 results)</a> as a filter for financial resilience.</li> <li>Hunt for potential mispricing by reviewing the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">220 high quality undervalued stocks</a> and see which names currently line up with stronger fundamentals than their prices imply.</li> <li>Add some off-the-radar ideas by browsing our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/global\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 566 high quality undiscovered gems</a>, a collection that highlights businesses the market may not be fully focused on yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if NIBE Industrier might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 00:18:03",
            "link": "https://simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares/news/a-look-at-nibe-industrier-omnibe-b-valuation-after-germanys",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Energy Recovery‚Äôs Valuation After Mixed 2025 Earnings And Recent Share Price Weakness",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Energy Recovery (ERII) shares are in focus after the company released fourth quarter and full year 2025 earnings, highlighting quarterly net income and earnings per share growth alongside slightly softer annual sales.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Energy Recovery.</a></p> <p>Despite the latest earnings update showing firmer quarterly profitability, the share price has come under pressure recently, with a 7 day share price return of 35.78% decline and a 1 year total shareholder return of 30.28% decline signaling fading momentum.</p> <p>If this pullback has you reassessing where you want exposure in the energy and infrastructure space, it could be a good moment to size up <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as potential alternatives or complements.</p> <p>With ERII trading at a steep discount to one set of analyst expectations and an indicated intrinsic discount, the key question is whether recent weakness leaves the shares undervalued or whether the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 42.8% Undervalued</h2> <p>Energy Recovery's most followed narrative pegs fair value at $18.24 per share, well above the last close of $10.43, which frames the current pullback in a very different light.</p> <blockquote> <p><em>Momentum in energy-efficient refrigeration (CO2 PX) technology adoption, supported by rigorous OEM engagement and reliability testing, aligns with global decarbonization trends and could lead to material incremental revenue streams and improved operating leverage.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/oyb4jtgs-global-water-scarcity-and-decarbonization-will-unlock-long-term-opportunities-vvt1\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what kind of revenue path and profit margins underpin that fair value, and how long term earnings power is modeled to get there, the full narrative lays out the numbers behind that story.</p> <p><strong>Result: Fair Value of $18.24 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/oyb4jtgs-global-water-scarcity-and-decarbonization-will-unlock-long-term-opportunities-vvt1\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this story can change quickly if desalination demand shifts toward alternative technologies or if extended OEM testing slows broader adoption of PX G and CO2 refrigeration.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Energy Recovery narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of opportunity and concern feels finely balanced, it makes sense to look at the key data yourself and decide where you stand, starting with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>Do not stop at a single stock. Widen your net with a few focused ideas from the Simply Wall St Screener so you are not second guessing later.</p> <ul> <li>Spot potential value plays early by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that currently look mispriced based on their fundamentals.</li> <li>Prioritise resilience by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a>, where companies earn stronger risk profiles and may better suit a steadier approach.</li> <li>Hunt for future leaders by reviewing a <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that the broader market may not be paying close attention to yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Energy Recovery might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/capital-goods/nasdaq-erii/energy-recovery/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 00:18:03",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery/news/assessing-energy-recoverys-valuation-after-mixed-2025-earnin",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Sotera Health (SHC) Is Down 7.1% After Issuing 2026 Revenue Guidance And Marking 20th Growth Year",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Sotera Health reported its fourth-quarter and full-year 2025 results on February 24, 2026, with revenue rising to US$303.44 million for the quarter and US$1.16 billion for the year, alongside higher net income and earnings per share.</li> <li>The company also issued 2026 revenue guidance of US$1.23 billion to US$1.25 billion and marked its 20th consecutive year of revenue growth, underscoring consistent demand for its sterilization and lab testing services.</li> <li>Next, we‚Äôll examine how Sotera Health‚Äôs 2026 revenue guidance and continued growth record influence its existing investment narrative and risk profile.</li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Sotera Health Investment Narrative Recap</h2><p>To own Sotera Health, you need to believe in steady demand for outsourced sterilization and lab testing, and in the company‚Äôs ability to manage heavy regulatory and legal headwinds around ethylene oxide. The latest results and 2026 guidance support the view that volume growth and pricing remain intact, but they do not materially change the key near term catalyst of execution on capacity and margin expansion, or the biggest risk around evolving EO regulations and litigation outcomes.</p> <p>The most relevant new development here is Sotera‚Äôs 2026 revenue guidance of US$1.233 billion to US$1.251 billion, which points to mid single digit growth after its 20th straight year of revenue increases. For investors focused on catalysts, this guidance helps frame how much of the expected upside still depends on sustained sterilization demand and successful capital deployment, while the backdrop of elevated regulatory driven spending and EO related legal exposure continues to shape the risk side of the story.</p> <p>Yet investors should also consider how ongoing EO litigation and regulatory costs could affect Sotera‚Äôs margins and cash generation...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/za706uvz-shc-recent-equity-offerings-and-lock-up-expiry-will-shape-market-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Sotera Health (it's free!)</a></p><p>Sotera Health's narrative projects $1.3 billion revenue and $314.2 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/za706uvz-shc-recent-equity-offerings-and-lock-up-expiry-will-shape-market-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Sotera Health's forecasts yield a $20.44 fair value</a>, a 26% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"SHC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/81d72a34-9c37-4c95-af9a-b5d1685a5c3b/chart/quote-price\" width=\"746\"/></a><figcaption>SHC 1-Year Stock Price Chart</figcaption></figure> <p>Before this update, the most cautious analysts were assuming revenue of about US$1.4 billion and earnings of roughly US$255 million by 2029, which sits well below more optimistic views and highlights how much opinions can diverge when you weigh EO litigation risks alongside the potential benefits of Nordion‚Äôs long term Cobalt 60 positioning.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on Sotera Health</a> - why the stock might be worth over 2x more than the current price!</p><h2>Decide For Yourself</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Sotera Health research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Sotera Health research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sotera Health's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 00:18:03",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/sotera-health-shc-is-down-71-after-issuing-2026-revenue-guid",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Colgate-Palmolive 2030 Plan Links AI Spending To Brand And Margin Goals",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Colgate-Palmolive (NYSE:CL) has started executing its 2030 Strategic Plan, with a focus on global brand strength, product innovation grounded in scientific research, and broader demand generation.</li> <li>The company is rolling out advanced digital tools and AI across its supply chain and organization as part of this multi-year plan.</li> <li>The plan is intended to reshape how Colgate-Palmolive competes in oral care, personal care, home care, and pet nutrition categories worldwide.</li> </ul> <p>For investors watching NYSE:CL, this new plan arrives with the shares at $99.14 and multi year returns that include 43.9% over 3 years and 46.7% over 5 years. In the shorter term, the stock shows returns of 4.3% over the past week, 16.6% over the past month, and 27.6% year to date. Together, these figures help frame how the market has been pricing recent company developments.</p> <p>As Colgate-Palmolive moves through the early phases of this 2030 plan, the main questions for investors will center on how effectively it uses AI, digital tools, and scientific research to support its brands and operations. Future reporting periods will help show whether this execution approach changes the company‚Äôs competitive position and efficiency in a meaningful way.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Colgate-Palmolive</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/CL\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Colgate-Palmolive.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:CL Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/882407e9-def3-41c4-aa3f-68d09426e47f/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:CL Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 3 risks for Colgate-Palmolive. See which could impact your investment.</a></p> <p>The 2030 Strategic Plan signals that Colgate-Palmolive is trying to tighten the link between its core strengths, such as brand equity in oral and personal care, and the operational engine behind them. For you as an investor, the interesting part is less the buzzwords around AI and more whether these tools genuinely lower costs, shorten product cycles and improve on-shelf execution across both developed and emerging markets. Using data, analytics and AI-powered tools in the supply chain and marketing could help Colgate-Palmolive respond more quickly to consumer trends and retailer demands, including in e-commerce channels where competitors like Procter &amp; Gamble, Unilever and Nestl√© are active.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Colgate-Palmolive Narrative</h3> <ul> <li>The plan to expand omnichannel reach and use digital tools is consistent with the narrative that positions emerging markets and premium oral care as long term growth drivers supported by better data and targeted marketing.</li> <li>Execution risk on restructuring and productivity programs could challenge the idea that cost savings will always be easy to reinvest while still supporting margins, especially if category growth in key markets is slower than analysts expect.</li> <li>The emphasis on AI and predictive analytics in the supply chain is an area that may not be fully captured in older narratives that focused more on product and geographic expansion than on back end efficiency gains.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/a7tksu28-cl-future-cost-optimization-will-drive-competitive-advantage-amid-category-headwinds\" rel=\"noopener noreferrer\" target=\"_blank\">Check out one of the top narratives in the Simply Wall St Community for Colgate-Palmolive</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Colgate-Palmolive is committing to multi year productivity and restructuring efforts, and if these projects disrupt operations or fall short on savings, the payoff from the 2030 plan could be limited.</li> <li>‚ö†Ô∏è The company faces category pressures and private label competition in several regions, so heavier digital and AI investment may not fully offset weaker volumes or pricing pressure in oral care and pet nutrition.</li> <li>üéÅ Colgate-Palmolive has strong global brands and exposure to emerging markets, and the 2030 plan aims to use science led product development and data driven marketing to support that position across oral care, personal care, home care and pet nutrition.</li> <li>üéÅ Analysts have identified rewards such as forecast earnings growth, a reliable dividend and a valuation that some models view as below estimated fair value, which frame how this long term plan might appeal to different investor profiles.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you may want to watch for concrete milestones on the 2030 plan, such as evidence of supply chain savings, new product launches backed by scientific claims and traction in e-commerce and omnichannel partnerships. Commentary around Hill‚Äôs Pet Nutrition and emerging markets like Latin America and India will also matter, given their role in previous analyst views of Colgate-Palmolive‚Äôs growth mix. Finally, pay attention to how management talks about reinvesting productivity gains into advertising and R&amp;D, and whether that shows up in brand share trends relative to peers such as Procter &amp; Gamble and Unilever.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Colgate-Palmolive, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/CL\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Colgate-Palmolive</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 00:18:03",
            "link": "https://simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive/news/colgate-palmolive-2030-plan-links-ai-spending-to-brand-and-m",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Disc Medicine stock moves after recent trading swings</h2> <p>Disc Medicine (IRON) has seen sharp share price swings recently, including a negative 1 day move and gains over the past week, drawing attention to how the market is currently reacting to its hematology focused pipeline.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Disc Medicine.</a></p> <p>Those recent swings come after a 30 day share price return of a 16.74% decline and a 90 day share price return of a 28.64% decline, even as the 1 year total shareholder return of 18.58% and 3 year total shareholder return of around 7x suggest longer term momentum has been stronger.</p> <p>If these moves in Disc Medicine have you thinking about where else growth stories might emerge in healthcare, it could be worth scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> as a starting point for other ideas.</p> <p>With Disc Medicine posting a 3 year return of around 7x, trading at about a 49% discount to the average analyst price target, and showing an estimated intrinsic discount near 82%, is there genuine upside left or is the market already pricing in future growth?</p> <h2>Preferred Price to Book of 3.4x, is it justified?</h2> <p>Disc Medicine currently trades on a P/B of 3.4x, which sits between its peer group and the broader US biotech industry. That mix of signals is what many investors are trying to interpret alongside the recent share price swings.</p> <p>P/B compares the company‚Äôs market value to the book value of its net assets. This can be a useful anchor for a business like Disc Medicine that is still in the clinical stage and unprofitable. With no revenue, forecast losses over the next three years, and a reported net loss of $212.18m, the market is effectively paying a multiple of the company‚Äôs balance sheet, pipeline and intellectual property rather than current earnings.</p> <p>On one hand, the 3.4x P/B is below the peer average of 5.2x, which suggests the company is priced lower than some direct comparables. On the other hand, it is above the wider US biotech industry average of 2.7x, which indicates investors are still assigning a premium to Disc Medicine relative to the sector overall, despite the company being unprofitable and forecast to have no revenue next year. There is also a large gap between the current share price of $66.62 and both the analyst price target of $99.36 and the SWS DCF model estimate of $369.15. The market could move closer to or further from those levels as new clinical data, funding developments or insider activity, including the recent significant insider selling, come through.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p><strong>Result: Price to Book ratio of 3.4x (ABOUT RIGHT)</strong></p> <p>However, there are still clear pressure points here, including a clinical stage pipeline with no current revenue and a recent net loss of $212.18m that could influence sentiment.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Disc Medicine narrative.</a></p> <h2>Another view: DCF points to a very different price</h2> <p>That 3.4x P/B might look roughly in line with the story so far, but our DCF model paints a very different picture. At a share price of $66.62 versus an estimated future cash flow value of $369.15, the model suggests Disc Medicine could be trading at a steep discount. Is this a genuine opportunity or a sign that the assumptions are too optimistic?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IRON Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/2bb88255-5b25-4ce7-bb16-867fff68cc39/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>IRON Discounted Cash Flow as at Feb 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">check out Disc Medicine for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Mixed signals or emerging story, either way, it makes sense to look at the full picture for yourself and move quickly if you want to form a clear stance. A useful starting point is <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 3 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Disc Medicine has sharpened your focus, do not stop here. Use the Simply Wall St screener to widen your watchlist with ideas that match your style.</p> <ul> <li>Target potential mispricings by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that combine solid fundamentals with what could be more attractive entry points.</li> <li>Strengthen the foundation of your portfolio by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (39 results)</a> that put financial resilience front and center.</li> <li>Hunt for future market standouts early by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before they land on everyone else‚Äôs radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 00:18:03",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/a-look-at-disc-medicine-iron-valuation-after-recent-share-pr",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "PrairieSky Royalty (TSX:PSK) Valuation Check After CEO‚Äôs Recent Insider Share Purchase",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>PrairieSky Royalty (TSX:PSK) is back on investor radar after CEO Andrew Phillips bought 5,000 common shares on February 26 at about CA$30.36, a direct insider purchase that can influence sentiment.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/ca/energy/tsx-psk/prairiesky-royalty-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for PrairieSky Royalty.</a></p> <p>That insider purchase comes as PrairieSky‚Äôs share price sits at CA$31.14, with a 30 day share price return of 7.75% and a year to date gain of 15.08%. The 1 year total shareholder return stands at 21.91% and the 5 year total shareholder return at 171.19%, suggesting momentum has been building over both shorter and longer periods.</p> <p>If this insider buying has you thinking about where else capital might flow in energy and resources, it could be a good time to scan <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_gold\" href=\"https://simplywall.st/discover/investing-ideas/473651/elite-gold-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">27 elite gold producer stocks</a> for potential ideas beyond PrairieSky.</p> <p>With PrairieSky trading close to its CA$32.50 analyst price target and carrying an indicated intrinsic discount of about 42%, the real question is whether the current price is a rare gap or if the market is already factoring in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 100% Overvalued</h2> <p>Compared with PrairieSky Royalty‚Äôs last close at CA$31.14, the most followed narrative points to a fair value of about CA$30.82 using a 6.1% discount rate.</p> <blockquote> <p><em>‚Ä¢ In order for you to agree with the analysts, you'd need to believe that by 2028, revenues will be CA$562.7 million, earnings will come to CA$282.3 million, and it would be trading on a PE ratio of 28.0x, assuming you use a discount rate of 6.1%.</em></p> </blockquote> <p><em>Read the complete narrative.</em> <a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/869b6hn3-update-for-prairiesky-royalty\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Want to see what is baked into that fair value? The narrative leans on steady revenue gains, fatter margins and a premium earnings multiple that is well above the sector. The full set of assumptions is where the real story sits.</p> <p><strong>Result: Fair Value of CA$30.82 (OVERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/869b6hn3-update-for-prairiesky-royalty\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, those assumptions could be challenged if drilling activity on key plays slows or if PrairieSky‚Äôs CA$281.7 million net debt limits its flexibility when conditions change.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/ca/energy/tsx-psk/prairiesky-royalty-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this PrairieSky Royalty narrative.</a></p> <h2>Another View: Cash Flows Paint a Different Picture</h2> <p>While the analyst narrative pegs PrairieSky Royalty at about CA$30.82 and calls the shares overvalued, our DCF model reaches a very different outcome. It points to a fair value around CA$53.33, which is roughly 41.6% above the current CA$31.14 price. Which set of assumptions do you think is closer to how PrairieSky will actually perform?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/ca/energy/tsx-psk/prairiesky-royalty-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/ca/energy/tsx-psk/prairiesky-royalty-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PSK Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/10148581-cf8c-4267-90dd-59d4c353bd06/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>PSK Discounted Cash Flow as at Feb 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/ca/energy/tsx-psk/prairiesky-royalty-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out PrairieSky Royalty for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Unsure which side of the PrairieSky story you lean toward after all this? Take a closer look at the data, weigh both the risks and the potential upsides, and let <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/ca/energy/tsx-psk/prairiesky-royalty-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a> help you size up the full picture before you decide what it means for you.</p> <h2>Ready to act on your investing ideas?</h2> <p>If PrairieSky has sharpened your focus, do not stop here, the next step is lining up a few more names that genuinely fit your goals.</p> <ul> <li>Target long term compounding potential by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 high quality undervalued stocks</a> with solid fundamentals that might not be fully appreciated yet.</li> <li>Strengthen your income stream by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/ca\" rel=\"noopener noreferrer\" target=\"_blank\">5 dividend fortresses</a> that could help anchor your portfolio with regular cash returns.</li> <li>Guard your downside by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 resilient stocks with low risk scores</a> that score well on quality and balance sheet resilience before sentiment catches up.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 00:11:42",
            "link": "https://simplywall.st/stocks/ca/energy/tsx-psk/prairiesky-royalty-shares/news/prairiesky-royalty-tsxpsk-valuation-check-after-ceos-recent",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Fortis' 52-Year Dividend Streak: Prudent Stability or Missed Upside for Regulated Utility Income? (TSX:FTS)",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Fortis recently extended its 52-year streak of annual dividend increases by lifting its quarterly payout by 4.1%, underscoring the stability of its regulated utility operations across Canada, the U.S., and the Caribbean.</li> <li>This combination of a higher dividend and a long record of consistent income, backed by regulated assets and planned grid and renewable investments, has reinforced Fortis‚Äôs appeal to investors seeking predictable cash flows.</li> <li>Next, we‚Äôll examine how Fortis‚Äôs latest dividend increase and emphasis on stable, regulated earnings influence its broader investment narrative.</li> </ul><p>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Fortis Investment Narrative Recap</h2><p>To own Fortis, you need to believe in the durability of regulated, essential utility services and the company‚Äôs ability to translate that into dependable earnings and dividends over time. The latest 4.1% dividend increase supports this income-focused thesis but does not materially change the key short term catalyst, which is execution on its capital investment program, or the main risk around regulatory and policy outcomes across its jurisdictions.</p> <p>Among recent announcements, the 2025 full year results, with higher sales and net income versus 2024, are most relevant to this dividend news. They show that Fortis‚Äôs growing regulated asset base is still converting into higher earnings, which supports the current dividend level and the company‚Äôs emphasis on stable, regulated returns as a core part of its investment story.</p> <p>Yet beneath this long dividend streak, investors still need to be aware of rising debt costs and regulatory pushback that could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/ca/utilities/tsx-fts/fortis-shares/nykvhb33-analysts-lift-fortis-price-target-amid-positive-profit-margin-outlook-and-key-developments\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Fortis (it's free!)</a></p><p>Fortis' narrative projects CA$13.8 billion revenue and CA$2.1 billion earnings by 2028. This requires 5.2% yearly revenue growth and about a CA$0.4 billion earnings increase from CA$1.7 billion today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/ca/utilities/tsx-fts/fortis-shares/nykvhb33-analysts-lift-fortis-price-target-amid-positive-profit-margin-outlook-and-key-developments\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Fortis' forecasts yield a CA$75.23 fair value</a>, a 4% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/ca/utilities/tsx-fts/fortis-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSX:FTS 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/1111771c-a897-4255-af4d-a3d130b7de9f/chart/quote-price\" width=\"746\"/></a><figcaption>TSX:FTS 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span about CA$75 to CA$156, reflecting very different expectations for Fortis. As you weigh those views, consider how interest coverage and regulatory lag could influence the company‚Äôs ability to sustain its current earnings profile over time, and why it is worth comparing several independent assessments before forming your own view.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/ca/utilities/tsx-fts/fortis-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Fortis</a> - why the stock might be worth just CA$75.23!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Fortis research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/ca/utilities/tsx-fts/fortis-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/ca/utilities/tsx-fts/fortis-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Fortis research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Fortis' overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">11 elite penny stocks</a> that balance risk and reward.</li><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 companies with promising cash flow potential yet trading below their fair value</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 00:11:42",
            "link": "https://simplywall.st/stocks/ca/utilities/tsx-fts/fortis-shares/news/fortis-52-year-dividend-streak-prudent-stability-or-missed-u",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Cogent Biosciences (COGT) Valuation After A Strong One Year Shareholder Return",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Stock performance snapshot and business context</h2> <p>Cogent Biosciences (COGT) has recently seen mixed share performance, with a 1.5% decline over the past day, a 4.0% gain over the past week, a 1.3% rise over the past month, and a 3.4% decline over the past 3 months.</p> <p>Year to date, the stock is up 11.8%, and the reported 1 year total return is 415.9%, with a 3 year total return of 187.9% and a 5 year total return of 389.9%.</p> <p>The company is a clinical stage biotechnology business focused on precision therapies for genetically defined diseases, with multiple product candidates in clinical trials targeting specific mutations in systemic mastocytosis, gastrointestinal stromal tumors, and other solid tumor indications.</p> <p>Cogent Biosciences reports revenue of US$0.0 and a net loss of US$328.937 million, which is typical for many early stage biotech firms that are still investing heavily in research and development.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Cogent Biosciences.</a></p> <p>At a share price of US$38.85, Cogent Biosciences has seen short term share price momentum soften recently, while the very large 1 year total shareholder return suggests earlier bullish sentiment around its clinical pipeline and perceived risk profile.</p> <p>If Cogent‚Äôs biotech story has your attention, it can be useful to compare it with other early stage healthcare names using our screener of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> as potential next ideas to research.</p> <p>With the shares at about US$38.85 after a very large 1 year total return, plus a value score of 1 and no current revenue, the key question is whether Cogent is still misunderstood or if the market already prices in future growth.</p> <h2>Preferred Price-to-Book of 11.4x: Is it justified?</h2> <p>At a last close of US$38.85, Cogent Biosciences trades on a P/B of 11.4x, sitting below its peer average but well above the broader US biotech group.</p> <p>P/B compares the market value of the company to its net assets. It is often used for early stage or loss making businesses where earnings are not yet meaningful. For a clinical stage biotech with no revenue and ongoing losses, a higher P/B can reflect how investors are weighing the company‚Äôs pipeline, expected future cash flows, and funding needs against its current balance sheet.</p> <p>Here, Cogent‚Äôs 11.4x P/B is described as good value relative to its peer average of 19.1x. This suggests the market is pricing the stock at a discount to similar names focused on comparable areas. At the same time, the same 11.4x is described as expensive versus the wider US biotechs industry average of 2.7x, meaning investors are currently assigning a much richer valuation than they are to the sector overall.</p> <p>Result: Price-to-Book of 11.4x (ABOUT RIGHT)</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p>However, you also have to weigh the pipeline and valuation against clinical trial uncertainty and the ongoing net loss of US$328.937 million with no current revenue.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Cogent Biosciences narrative.</a></p> <h2>Next Steps</h2> <p>If you are weighing the mix of strong past returns and a significant net loss, take a moment to review the key data and form your own view, including the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 3 important warning signs</a> that highlights what the market currently sees on both the risk and reward side.</p> <h2>Looking for more investment ideas?</h2> <p>If Cogent has you thinking more broadly about your portfolio, do not stop here, there are other stocks and themes worth putting on your radar right now.</p> <ul> <li>Target potential mispricings by scanning companies that look attractively valued on key fundamentals using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> before the crowd turns its attention to them.</li> <li>Strengthen your income stream by reviewing companies with higher yields and resilient payouts through the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> so you are not relying on capital gains alone.</li> <li>Prioritise resilience by focusing on businesses with robust finances and consistent metrics via the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (39 results)</a>, rather than leaving your capital tied to weaker balance sheets.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 00:11:42",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/a-look-at-cogent-biosciences-cogt-valuation-after-a-strong-o",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Portland General Electric (POR) Valuation After Equity Raises And PacifiCorp Acquisition News",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Portland General Electric (POR) has quickly moved into the spotlight after completing follow-on equity offerings of about US$480 million and agreeing to buy PacifiCorp utility assets in Washington state, which are linked to growing generative AI power demand.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/utilities/nyse-por/portland-general-electric\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Portland General Electric.</a></p> <p>Alongside the follow on equity offerings and PacifiCorp acquisition plans, Portland General Electric‚Äôs share price has been firm, with an 8.1% 1 month share price return and 11.4% year to date share price return suggesting momentum has been building off the back of these updates. Over a longer stretch, a 26.2% 1 year total shareholder return and 53.0% 5 year total shareholder return indicate that investors who stayed invested through recent capital raises and earnings movements have, so far, been rewarded.</p> <p>If the AI linked power demand story has you looking beyond a single utility, this could be a good moment to scan <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as a starting list of grid focused names to research next.</p> <p>So with Portland General Electric raising about US$480 million, reporting US$306 million in net income, and leaning into AI related demand, is the current share price offering value or is the market already pricing in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 3.1% Overvalued</h2> <p>Portland General Electric‚Äôs most followed narrative puts fair value at about $52.32, slightly below the last close of $53.96, which frames the current AI and PacifiCorp excitement as already largely reflected in the price.</p> <blockquote> <p><em>Robust and sustained demand growth from industrial and data center customers is accelerating system wide electricity usage, underpinned by Oregon's strong technology sector and regional electrification objectives; this is expected to solidly grow PGE's revenue base and support long term earnings expansion.</em></p> </blockquote> <p><em>Ongoing transition to clean energy including major renewable procurements (2023 and 2025 RFPs) and battery storage integration position PGE to capitalize on declining renewable costs and federal tax credits, which should drive rate base growth, lower operational costs, and support future margin improvement.</em></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/dlz3g6mc-analyst-commentary-highlights-raised-targets-and-battery-storage-gains-for-portland-general-electric\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious how steady demand, cleaner generation, and a higher future earnings multiple all fit into one price tag? The key assumptions behind this fair value hinge on revenue growth, margin expansion, and where the P/E could settle a few years from now. If you want to see exactly how those moving parts are wired together, the full narrative lays out the numbers behind that $52.32 figure.</p> <p><strong>Result: Fair Value of $52.32 (OVERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/dlz3g6mc-analyst-commentary-highlights-raised-targets-and-battery-storage-gains-for-portland-general-electric\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, there is still the risk that rising clean energy and grid investment costs are not fully recovered in rates, or that Oregon-focused exposure amplifies any local downturn.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/utilities/nyse-por/portland-general-electric\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Portland General Electric narrative.</a></p> <h2>Another View: Earnings Multiple Paints a Tighter Picture</h2> <p>While the narrative model suggests Portland General Electric is about 3.1% overvalued at $53.96 versus a fair value of $52.32, the current P/E of 20.4x sits below both the fair ratio of 21.5x and the US Electric Utilities average of 22.5x, as well as a 25.7x peer average. That gap points to less froth and more of a valuation tug of war, so which signal do you trust more?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/utilities/nyse-por/portland-general-electric/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/utilities/nyse-por/portland-general-electric/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:POR P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/8fb5bd83-9954-4c24-9c26-b5498b31469c/chart/pe-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:POR P/E Ratio as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>If this mix of AI optimism and valuation questions has you thinking hard, do not wait too long to review the full picture for yourself and weigh up the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/utilities/nyse-por/portland-general-electric\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Portland General Electric has sharpened your focus on where to put fresh capital next, do not stop here. Give yourself options before the market moves on.</p> <ul> <li>Target quality first with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a>, which combine solid fundamentals with prices that may not fully reflect their strengths yet.</li> <li>Prioritise resilience by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a>, which score well on stability so you are not relying on luck when conditions get tougher.</li> <li>Hunt for future standouts through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before they get crowded and the early opportunity thins out.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 00:11:42",
            "link": "https://simplywall.st/stocks/us/utilities/nyse-por/portland-general-electric/news/assessing-portland-general-electric-por-valuation-after-equi",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is It Time To Reassess Public Storage (PSA) After Recent Share Price Strength",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Public Storage is fairly priced at around US$307 a share, you are not alone; many investors are trying to work out what they are actually paying for here.</li> <li>The stock has recently posted returns of 0.7% over 7 days, 12.1% over 30 days, 18.8% year to date, 5.4% over 1 year, 13.9% over 3 years, and 61.9% over 5 years, which is prompting fresh questions about both growth potential and risk.</li> <li>Recent coverage has focused on Public Storage as a major US self storage REIT, with investors paying close attention to how the business model fits into the broader real estate sector and demand for storage space. This backdrop helps explain why the market is actively reassessing what a reasonable price might be for the shares today.</li> <li>Right now, our framework gives Public Storage a value score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/real-estate/nyse-psa/public-storage/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">4 out of 6</a>, which reflects the number of checks where the stock screens as undervalued. Next, we will walk through the key valuation approaches behind that score, and then finish with a way of looking at valuation that goes a step further.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_performance_contextual\" href=\"https://www.simplywall.st/stocks/us/real-estate/nyse-psa/public-storage/past\" rel=\"noopener noreferrer\" target=\"_blank\">Public Storage delivered 5.4% returns over the last year. See how this stacks up to the rest of the Specialized REITs industry.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Public Storage Discounted Cash Flow (DCF) Analysis</h3> <p>The DCF model here takes Public Storage‚Äôs adjusted funds from operations, projects them into the future, then discounts those cash flows back to today‚Äôs dollars to estimate what the business might be worth right now.</p> <p>On this basis, Public Storage is modeled using a 2 stage Free Cash Flow to Equity approach built on adjusted funds from operations. The latest twelve month free cash flow is about $2.78b. Analyst and extrapolated estimates suggest free cash flow reaching around $3.70b by 2030, with a path that moves through projected figures such as $2.81b in 2026 and $3.46b in 2029, all in US dollars.</p> <p>After discounting these projected cash flows, the model arrives at an estimated intrinsic value of about $462.30 per share. Compared with the current share price of around $307, this implies a 33.6% discount, which indicates that the shares screen as undervalued under this particular set of assumptions.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Public Storage is undervalued by 33.6%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/real-estate/nyse-psa/public-storage/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PSA Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/bfbc8a79-e724-403f-9cd8-11f09d230631/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>PSA Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/real-estate/nyse-psa/public-storage/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Public Storage.</a></p> <h3>Approach 2: Public Storage Price vs Earnings</h3> <p>For a profitable company like Public Storage, the P/E ratio is a straightforward way to see what investors are paying for each dollar of earnings. It captures both what the business is earning today and how the market is weighing its prospects and risks.</p> <p>In general, higher growth expectations and lower perceived risk can support a higher P/E, while slower growth or higher risk usually line up with a lower, more cautious multiple. The question is not whether a P/E is high or low in isolation, but whether it makes sense given the company‚Äôs profile.</p> <p>Public Storage currently trades on a P/E of 33.99x. That sits above the Specialized REITs industry average of 15.86x, and below the peer group average of 41.55x. Simply Wall St‚Äôs Fair Ratio for Public Storage is 34.36x, which is its proprietary estimate of a suitable P/E given the company‚Äôs earnings growth, industry, profit margins, market cap and key risks. This Fair Ratio can be more informative than a simple peer or industry comparison because it tries to account for the specific mix of growth, risk and profitability that is unique to Public Storage.</p> <p>With the current P/E of 33.99x very close to the Fair Ratio of 34.36x, the shares screen as ABOUT RIGHT on this metric.</p> <p><strong>Result: ABOUT RIGHT</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/real-estate/nyse-psa/public-storage/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:PSA P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/bfbc8a79-e724-403f-9cd8-11f09d230631/chart/pe-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:PSA P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Public Storage Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. Narratives let you turn your view of Public Storage into a clear story that links its business outlook to a financial forecast, then to a fair value, all inside Simply Wall St‚Äôs Community page where millions of investors share their assumptions. You can compare a more upbeat view that leans toward the higher US$350 price target with a more cautious view closer to US$287, see how each Narrative‚Äôs fair value stacks up against today‚Äôs share price, and watch those fair values update automatically as new earnings, guidance or news come through. This can give you a practical framework to decide whether the current price lines up with your own expectations.</p> <p>Do you think there's more to the story for Public Storage? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NYSE/PSA\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/real-estate/nyse-psa/public-storage\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:PSA 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/bfbc8a79-e724-403f-9cd8-11f09d230631/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:PSA 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 00:11:42",
            "link": "https://simplywall.st/stocks/us/real-estate/nyse-psa/public-storage/news/is-it-time-to-reassess-public-storage-psa-after-recent-share",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Technology One (ASX:TNE) Is Up 5.3% After Upgrading FY26 SaaS Guidance And Insider Buying - Has The Bull Case Changed?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Technology One Limited recently increased its FY26 guidance, forecasting higher profit before tax growth and stronger annual recurring revenue, reflecting confidence in SaaS and SaaS+ demand across Australia, New Zealand and the UK.</li> <li>This guidance upgrade comes alongside ongoing board evolution and insider share purchases, underscoring management‚Äôs alignment with and commitment to the company‚Äôs SaaS-focused trajectory.</li> <li>We‚Äôll now explore how the upgraded profit and recurring revenue guidance could influence Technology One‚Äôs existing investment narrative and risk profile.</li> </ul><p>Find <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/au\" rel=\"noopener noreferrer\" target=\"_blank\">8 companies with promising cash flow potential yet trading below their fair value</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Technology One Investment Narrative Recap</h2><p>To be comfortable owning Technology One, you have to believe its shift to SaaS and now SaaS+ can keep driving dependable recurring revenue while justifying a relatively high earnings multiple. The upgraded FY26 profit and ARR guidance reinforces that storyline and likely strengthens the near term catalyst around recurring revenue growth. At the same time, it does not remove the key risk that expectations embedded in the current valuation could still prove demanding if growth slows.</p> <p>Among the recent announcements, the upgraded FY26 guidance is the most directly relevant. Lifting profit before tax growth expectations to 18% to 20% and ARR growth to 16% to 18% gives more concrete shape to the SaaS+ thesis that many investors are watching closely. Combined with continuing board refreshment and Philip Davis‚Äô initial on market share purchase, it supports a narrative of management leaning into the recurring revenue opportunity while the market reassesses shorter term share price weakness.</p> <p>But against this stronger guidance, investors should still weigh the risk that Technology One‚Äôs premium valuation could come under pressure if revenue growth in key markets were to...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/software/asx-tne/technology-one-shares/nfnd5wy8-overvaluation-will-encounter-regulatory-headwinds-and-saas-resilience-hxrs\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Technology One (it's free!)</a></p><p>Technology One‚Äôs narrative projects A$841.0 million revenue and A$224.2 million earnings by 2028. This requires 15.1% yearly revenue growth and an earnings increase of about A$91 million from A$133.0 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/software/asx-tne/technology-one-shares/nfnd5wy8-overvaluation-will-encounter-regulatory-headwinds-and-saas-resilience-hxrs\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Technology One's forecasts yield a A$34.87 fair value</a>, a 34% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:TNE 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/bb9a9557-2c31-4c59-ae97-fee24edc380a/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:TNE 1-Year Stock Price Chart</figcaption></figure> <p>Some analysts were far more cautious, assuming A$857.6 million of revenue and A$219.6 million of earnings by 2028, so this guidance upgrade may eventually shift their more pessimistic view.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 7 other fair value estimates on Technology One</a> - why the stock might be worth as much as 34% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Technology One research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Technology One research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Technology One's overall financial health at a glance.</li></ul><h2>Seeking Other Investments?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/au\" rel=\"noopener noreferrer\" target=\"_blank\">7 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Technology One might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/au/software/asx-tne/technology-one-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 00:05:54",
            "link": "https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares/news/technology-one-asxtne-is-up-53-after-upgrading-fy26-saas-gui",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is FulcrumAir Robotics Partnership Reshaping the Investment Case for Preformed Line Products (PLPC)?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, FulcrumAir announced a new multi-year partnership with Preformed Line Products to co-develop next-generation robotic systems for overhead power line construction, targeting improved efficiency, safety, and reliability for utilities worldwide. </li> <li>This expanded collaboration builds on earlier joint products like the LineSpider and LineFly robots, highlighting how automation could reshape how utilities build and maintain critical grid infrastructure. </li> <li>Next, we will examine how this focus on advanced robotic installation systems may influence Preformed Line Products‚Äô broader investment narrative. </li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is Preformed Line Products' Investment Narrative?</h2><p>For someone considering Preformed Line Products, the big picture is about believing in steady grid investment and PLP‚Äôs ability to keep turning specialized hardware and systems into resilient earnings, despite some volatility. The new FulcrumAir partnership fits neatly into this narrative: it reinforces PLP‚Äôs position in automated installation systems, but is unlikely to be a near term financial needle-mover compared with more immediate catalysts like order flow from utilities, margin trends after a softer Q3 2025, and how the business justifies its current premium P/E multiple. Where it might matter more is on the risk side: deeper integration into robotics raises execution and R&amp;D risk, but also gives PLP another way to defend its niche if competition in more traditional products intensifies.</p> But there is one operational and valuation risk in particular that investors should not ignore.\n\nPreformed Line Products' share price has been on the slide but might be dropping deeper into value territory. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Find out whether it's a bargain at this price</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PLPC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/92e40fc7-c157-465d-983d-ab7b75e39451/chart/quote-price\" width=\"746\"/></a><figcaption>PLPC 1-Year Stock Price Chart</figcaption></figure> Two Simply Wall St Community fair value estimates span roughly US$77 to US$285, showing just how far apart private investors can be on PLP. When you set those views against the recent robotics partnership and the company‚Äôs premium earnings multiple, it underlines why understanding both growth ambitions and execution risks could matter for future performance.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on Preformed Line Products</a> - why the stock might be worth as much as 12% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Preformed Line Products research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Preformed Line Products research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Preformed Line Products' overall financial health at a glance.</li></ul><h2>Searching For A Fresh Perspective?</h2><p>Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 smaller AI-focused companies with strong growth potential</a> through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 00:05:54",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products/news/is-fulcrumair-robotics-partnership-reshaping-the-investment",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Ipsos (ENXTPA:IPS) Valuation After Mixed Recent Share Performance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Recent share performance and context</h2> <p>Ipsos (ENXTPA:IPS) has seen mixed share performance recently, with a 2.2% decline over the past day, a 10.9% gain over the past week, and a 3.7% decline over the past month.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/fr/media/epa-ips/ipsos-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Ipsos.</a></p> <p>At a share price of ‚Ç¨34.46, Ipsos has seen momentum fluctuate, with a 7.4% 90 day share price return set against a 25.0% decline in 1 year total shareholder return, pointing to shorter term strength after a tougher period.</p> <p>If this shift in sentiment has you looking further afield, it could be a good moment to uncover high potential names using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/global\" rel=\"noopener noreferrer\" target=\"_blank\">96 top founder-led companies</a>.</p> <p>With Ipsos trading at ‚Ç¨34.46 and both analyst targets and intrinsic estimates sitting much higher, the market seems cautious about its survey and data business. Is this a genuine opportunity, or is expected growth already priced in?</p> <h2>Most Popular Narrative: 40.2% Undervalued</h2> <p>With Ipsos last closing at ‚Ç¨34.46 against a narrative fair value of ‚Ç¨57.61, the current share price sits well below what this widely followed view suggests.</p> <blockquote> <p><em>Rapid advancements in AI and digital platforms (such as synthetic data, PersonaBots, Digital Twin Panels, and Ipsos Digital) are driving faster, more actionable insights for clients across industries, improving operational efficiency, unlocking new solutions, and contributing to structurally higher net margins and earnings thanks to a more scalable, higher margin business mix.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/dtgji4jg-leadership-transition-and-new-partnerships-will-shape-future-customer-experience-success\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what kind of revenue trajectory and margin profile could justify that gap between fair value and price? The narrative leans on compounding earnings power, disciplined cost control, and a richer mix of higher margin work. The real story sits in how these pieces are modelled together over the next few years.</p> <p><strong>Result: Fair Value of ‚Ç¨57.61 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/dtgji4jg-leadership-transition-and-new-partnerships-will-shape-future-customer-experience-success\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, that upside story could fray if public sector budgets tighten more than expected, or if recent acquisitions weigh on group margins longer than analysts anticipate.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/fr/media/epa-ips/ipsos-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Ipsos narrative.</a></p> <h2>Next Steps</h2> <p>With that mix of optimism and caution in mind, it makes sense to look at the full picture yourself and decide quickly where you stand, starting with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/fr/media/epa-ips/ipsos-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Ipsos has sharpened your thinking, do not stop here. Use our screeners to quickly surface fresh ideas that fit the way you like to invest.</p> <ul> <li>Target potential mispricings by scanning our market wide list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">220 high quality undervalued stocks</a> that combine solid fundamentals with attractive pricing signals.</li> <li>Prioritise resilience by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/global\" rel=\"noopener noreferrer\" target=\"_blank\">325 resilient stocks with low risk scores</a> that score well on stability so you are not relying on just one name to manage volatility.</li> <li>Get ahead of the crowd by reviewing our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/global\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 566 high quality undiscovered gems</a> before they appear on everyone else's radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 00:05:54",
            "link": "https://simplywall.st/stocks/fr/media/epa-ips/ipsos-shares/news/assessing-ipsos-enxtpaips-valuation-after-mixed-recent-share",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Cohen & Steers (CNS) Valuation As Its Quarterly Dividend Is Raised To $0.67 Per Share",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Cohen &amp; Steers (CNS) has drawn investor attention after its Board of Directors approved a first quarter 2026 cash dividend of $0.67 per share, up from $0.62, payable on March 19.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Cohen &amp; Steers.</a></p> <p>Despite the higher dividend, Cohen &amp; Steers‚Äô recent trading has been mixed, with a 30-day share price return of 4.35% and a year to date share price return of 4.97%. However, the 1-year total shareholder return is a 21.13% decline, suggesting only modest momentum after a weaker year.</p> <p>If this income focused update has you thinking about where else yield and growth might intersect, it could be worth scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a> for fresh ideas beyond asset managers.</p> <p>With revenue of US$556.1m, net income of US$153.2m and a higher quarterly dividend now on the table, is Cohen &amp; Steers trading at a discount, or are markets already pricing in its future growth potential?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 7.3% Undervalued</h2> <p>With Cohen &amp; Steers last closing at $66.73 versus a narrative fair value of $72.00, the current setup hinges on how its real assets focus plays out.</p> <blockquote> <p><em>Strategic expansion into active ETFs and broader product diversification (including the launch of integrated listed/private real estate strategies) is expected to attract new investor segments and improve client retention, supporting future AUM growth and revenue stability.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/zwi3684f-active-etfs-and-global-distribution-will-drive-enduring-market-success-0fr9\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what is driving that fair value gap? The narrative leans heavily on higher earnings, richer margins and a different P/E profile than today. The full story is in the numbers.</p> <p><strong>Result: Fair Value of $72 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/zwi3684f-active-etfs-and-global-distribution-will-drive-enduring-market-success-0fr9\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, there are still watchpoints, including ongoing client outflows tied to allocation shifts, as well as rising costs from global expansion and new product launches that could pressure margins.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Cohen &amp; Steers narrative.</a></p> <h2>Another Take On Valuation</h2> <p>That $72 fair value from the narrative sits alongside a different signal from earnings based pricing. Cohen &amp; Steers trades on a P/E of 22.2x, which is below the US Capital Markets average of 23.4x but above our fair ratio of 15.3x. So is this a quality premium or just valuation risk building up?</p> <p>To see how those P/E gaps stack up against history and peers in a bit more detail, <a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a> can help you pressure test whether the current price feels comfortable for your own risk tolerance.</p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-cns/cohen-steers/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:CNS P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/16375567-5596-4006-a545-c3cc054a6e10/chart/pe-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:CNS P/E Ratio as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>If this mix of income appeal and valuation questions leaves you on the fence, now is a good time to review the full picture yourself, including <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Cohen &amp; Steers is only one piece of your watchlist, now is the moment to line up a few more ideas before the next move catches you off guard.</p> <ul> <li>Spot income opportunities by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that may appeal if you want yields with a focus on resilience.</li> <li>Hunt for potential value by checking <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> where solid fundamentals meet prices that some investors may see as appealing.</li> <li>Strengthen your watchlist with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a> that aim to balance return potential with lower overall risk scores.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 00:05:54",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers/news/a-look-at-cohen-steers-cns-valuation-as-its-quarterly-divide",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Cloudflare Deepens Security Role With Post Quantum SASE And Mastercard Pact",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Cloudflare launched what it calls the first complete Secure Access Service Edge platform with post-quantum encryption across its services.</li> <li>The company also announced a cybersecurity partnership with Mastercard aimed at protecting critical infrastructure and small businesses with real time, risk driven defenses.</li> </ul> <p>Cloudflare, trading on the NYSE under ticker NYSE:NET, sits at the intersection of networking and security. This move pushes more of its product stack into the security spotlight. The stock last closed at $172.19, with a 1 year return of 18.5% and a 3 year return of 179.6%. These figures put the announcements into focus for investors following the company's evolution. The 5 year return of 156.9% offers a longer lens on how the market has treated Cloudflare's role in internet infrastructure.</p> <p>In the near term, investors watching NYSE:NET are likely to focus on how post-quantum encryption and the Mastercard partnership translate into product adoption and customer stickiness. As quantum computing risk and attacks on payment systems and small businesses receive more attention, Cloudflare's positioning around end to end cryptography and real time threat screening may become a more central part of how the company is evaluated.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Cloudflare</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/NET\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Cloudflare.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:NET Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/46496791-fd68-4f67-818a-7ac8ce86e3d7/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:NET Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 1 risk for Cloudflare. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At US$172.19 versus a consensus target of about US$231.30, the price sits roughly 34% below where analysts, on average, think it could be.</li> <li><strong>‚ùå Simply Wall St Valuation</strong>: The shares are described as trading 70.8% above an estimated fair value, which flags a rich valuation on that model.</li> <li><strong>‚ùå Recent Momentum</strong>: A 30 day return of about 6.9% decline suggests recent pressure despite the product and partnership news.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Cloudflare: head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Cloudflare's Fair Value.</a></p> <h3>Key Considerations</h3> <ul> <li>üìä The SASE launch with post quantum encryption, plus the Mastercard tie up, pushes Cloudflare deeper into security and payments adjacent workloads, which some investors may see as broadening its role in internet infrastructure.</li> <li>üìä Watch how large customers adopt the new SASE offering, any traction in deals linked to Mastercard, and whether revenue and earnings forecasts are updated in response.</li> <li>‚ö†Ô∏è With one flagged risk around recent insider selling and shares sitting well above an estimated fair value, execution on these products will be important if sentiment cools.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture, including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare\" rel=\"noopener noreferrer\" target=\"_blank\">complete Cloudflare analysis</a>. Alternatively, you can check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/NET\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Cloudflare</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 00:05:54",
            "link": "https://simplywall.st/stocks/us/software/nyse-net/cloudflare/news/cloudflare-deepens-security-role-with-post-quantum-sase-and",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Does First Bancorp (FBNC)‚Äôs Liquidity Playbook Clarify or Complicate Its Profitability Story?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In its recently filed 2025 10-K, First Bancorp outlined past actions to strengthen liquidity and capital, including reinvesting in higher-yielding securities and maintaining a diversified deposit base, while reporting a 14.4% increase in shareholders‚Äô equity and a CET1 ratio of 14.10%.</li> <li>The filing also underscored a business mix shift toward more variable-rate loans and relatively weak revenue growth and net interest margin versus peers, sharpening investor focus on how the bank manages interest rate risk and profitability.</li> <li>We‚Äôll now examine how First Bancorp‚Äôs emphasis on maintaining a diversified deposit base shapes the company‚Äôs broader investment narrative.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is First Bancorp's Investment Narrative?</h2><p>To own First Bancorp today, you have to be comfortable with a fairly traditional, relationship-focused regional bank that is trying to balance slower growth with a strong capital and liquidity profile. The 2025 10-K reinforces that story: management is leaning into a diversified deposit base, higher-yielding securities and a thicker capital cushion, with CET1 at 14.10% and shareholders‚Äô equity up 14.4%. That is reassuring given recent volatility in bank funding costs, and it supports the near-term dividend story after the latest increase to US$0.24 per share. At the same time, the filing also puts a spotlight on the weak revenue growth, a 3.1% net interest margin and a greater tilt toward variable-rate loans, which keeps interest rate risk, funding competition and the stock‚Äôs above-peer valuation firmly on the list of near-term swing factors.</p> However, investors should not ignore how interest rate sensitivity could pressure margins if conditions shift.\n\nDespite retreating, First Bancorp's shares might still be trading 41% above their fair value. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/us/banks/nasdaq-fbnc/first-bancorp/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Discover the potential downside here</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/banks/nasdaq-fbnc/first-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"FBNC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/18aaef02-f6ad-4640-bf94-5195b7c7866f/chart/quote-price\" width=\"746\"/></a><figcaption>FBNC 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span roughly US$54 to almost US$97 per share, underlining how far apart individual views can be. Set against concerns over First Bancorp‚Äôs weaker net interest margin and rising interest rate sensitivity, that spread in opinions invites you to weigh how much value you place on its capital strength versus profitability risk.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/banks/nasdaq-fbnc/first-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on First Bancorp</a> - why the stock might be worth as much as 70% more than the current price!</p><h2>Decide For Yourself</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your First Bancorp research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/banks/nasdaq-fbnc/first-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/banks/nasdaq-fbnc/first-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\">Our free First Bancorp research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate First Bancorp's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>Outshine the giants: these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 early-stage AI stocks could fund your retirement</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 23:56:38",
            "link": "https://simplywall.st/stocks/us/banks/nasdaq-fbnc/first-bancorp/news/does-first-bancorp-fbncs-liquidity-playbook-clarify-or-compl",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Celsius Revenue Record Expands Beverage Platform And Raises Valuation Questions",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Celsius Holdings (NasdaqCM:CELH) reported record full year revenue in 2025.</li> <li>Results were driven by the acquisitions and integration of Alani Nu and Rockstar Energy.</li> <li>The company further integrated into the PepsiCo system and expanded internationally.</li> <li>Celsius launched a new brand studio and a Fizz Free product line during 2025.</li> </ul> <p>Celsius Holdings operates in the energy drink category, a segment that continues to attract strong consumer attention as shoppers look for functional beverages and brand variety. The 2025 tie up with Alani Nu and Rockstar Energy adds more labels and distribution reach to the portfolio, while working within the PepsiCo system gives Celsius access to scaled retail channels. For investors, the story now extends beyond a single flagship brand into a broader beverage platform.</p> <p>The latest results also highlight how Celsius is pushing outside its core US base with wider international distribution and new product formats such as Fizz Free. As you think about NasdaqCM:CELH, the key questions become how effectively the company can sustain demand across regions, manage multiple brands under one umbrella, and keep execution tight as its footprint grows.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-celh/celsius-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Celsius Holdings</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NasdaqCM/CELH\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Celsius Holdings.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-celh/celsius-holdings/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:CELH Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/c3cebf6a-9bfa-4ee6-a737-955efc93c0da/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqCM:CELH Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_hidden_strengths\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-celh/celsius-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">2 things going right for Celsius Holdings that this headline doesn't cover.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At US$53.61 versus a consensus target of US$66.30, the price sits about 19% below where analysts see it.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Simply Wall St estimates the shares are trading 26.9% below fair value, which aligns with an undervalued status.</li> <li><strong>‚ùå Recent Momentum</strong>: The 30 day return of roughly 0.6% decline shows the share price has cooled despite the record revenue headline.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Celsius Holdings. Head to the Simply Wall St\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-celh/celsius-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Celsius Holdings's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä Record 2025 revenue, the Alani Nu and Rockstar integration, and deeper PepsiCo distribution all contribute to a broader beverage platform that investors can now assess beyond a single brand.</li> <li>üìä Keep an eye on how international sales, the Fizz Free line, and any cross selling between acquired brands filter through to margins and earnings, relative to the current P/E of 215.7x and forward P/E of 35.3x.</li> <li>‚ö†Ô∏è Profit margins of 2.5% sit well below the beverage industry average of 12.7%, and previous one off items have affected results, so the quality and stability of earnings are key watchpoints.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture, including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-celh/celsius-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">complete Celsius Holdings analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NasdaqCM/CELH\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Celsius Holdings</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 23:56:38",
            "link": "https://simplywall.st/stocks/us/food-beverage-tobacco/nasdaq-celh/celsius-holdings/news/celsius-revenue-record-expands-beverage-platform-and-raises",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Slide Insurance Holdings (SLDE) Valuation After Recent Share Price Momentum",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>With no specific headline event driving Slide Insurance Holdings (SLDE) today, recent trading and fundamentals provide more of the story. The stock last closed at $19.00, with mixed short term returns.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/insurance/nasdaq-slde/slide-insurance-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Slide Insurance Holdings.</a></p> <p>The recent 7 day share price return of 12.6% and 30 day share price return of 18.9%, on top of a positive 90 day share price move, point to building momentum despite a softer 1 day pullback.</p> <p>If this kind of move has you looking beyond a single insurer, it could be a helpful moment to broaden your search and check out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a> for more ideas.</p> <p>With Slide Insurance Holdings trading at $19.00 against an analyst price target of $24.60 and an indicated intrinsic value gap, the key question is whether this represents an undervalued insurer or a stock that already reflects expectations of future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 17.4% Undervalued</h2> <p>Slide Insurance Holdings' most followed narrative pegs fair value at $23, compared with the latest close at $19. That gap rests on some specific growth and profitability assumptions that investors may want to understand.</p> <blockquote> <p><em>Use of proprietary ProCast technology and a data heavy underwriting approach, coupled with a conservative reserving philosophy, is intended to keep underwriting discipline as the book seasons, which can influence future loss ratios, net margins and return on equity.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/7fou8z9l-update-for-slide-insurance-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what earnings profile and margin structure sit behind that $23 fair value tag? The narrative focuses on compounding revenue, changing profitability, and a re rated earnings multiple. Investors may want to understand how those elements interact.</p> <p><strong>Result: Fair Value of $23 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/7fou8z9l-update-for-slide-insurance-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this narrative can be challenged if a heavier catastrophe season lifts loss and combined ratios, or if Florida focused growth and Citizens takeouts face tougher regulation or pricing.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/insurance/nasdaq-slde/slide-insurance-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Slide Insurance Holdings narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of upside potential and clear risks leaves you undecided, act while the data is fresh and test the thesis yourself with <a class=\"company-report-links\" data-vars-link-type=\"cta_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/insurance/nasdaq-slde/slide-insurance-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards</a>.</p> <h2>Looking for more investment ideas?</h2> <p>Before you move on, give yourself the chance to spot opportunities you might otherwise miss by scanning other stocks that fit your style and risk tolerance.</p> <ul> <li>Target reliable income by reviewing companies in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that focus on stronger yield profiles.</li> <li>Hunt for potential mispricings with the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that highlight quality names the market may not be focusing on yet.</li> <li>Prioritise capital protection by checking stocks flagged in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a> that emphasise resilience over headline excitement.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 23:56:38",
            "link": "https://simplywall.st/stocks/us/insurance/nasdaq-slde/slide-insurance-holdings/news/assessing-slide-insurance-holdings-slde-valuation-after-rece",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Bausch + Lomb (BLCO) Valuation After Strong Q4 Growth And Vision 27 Margin Progress",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Bausch + Lomb (BLCO) is back in focus after reporting record Q4 2025 revenue and adjusted EBITDA growth, supported by pharmaceuticals, premium intraocular lenses, contact lenses, and the Vision 27 margin improvement program.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Bausch + Lomb.</a></p> <p>The record Q4 figures, guidance for 2026 revenue in the US$5.375b to US$5.475b range and fresh clinical attention on products like LUMIFY sit against a share price of US$18.30, with a 30 day share price return of 9.19% and a 1 year total shareholder return of 14.37%. This suggests that momentum has been building rather than fading over the past quarter.</p> <p>If this kind of healthcare news has your attention, it could be a good moment to broaden your watchlist with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> identified by our screener as potential next ideas to research.</p> <p>With revenue at US$5.1b, ongoing net losses and a share price sitting just below the average analyst target, the real question is whether Bausch + Lomb is still trading at a discount or if the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 6.1% Overvalued</h2> <p>Compared with Bausch + Lomb's last close at $18.30, the most followed narrative pegs fair value at $17.25, suggesting the current price sits modestly above that line.</p> <blockquote> <p><em>Analysts are assuming Bausch + Lomb's revenue will grow by 5.7% annually over the next 3 years. Analysts assume that profit margins will increase from 6.1% today to 4.3% in 3 years time.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/m1vgk3ap-update-for-bausch-lomb\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious how a company with current losses still earns a premium style valuation? The narrative leans heavily on future margin repair, faster earnings growth and a richer multiple than the sector usually commands. The key ingredients are all laid out, but the exact mix is where things get interesting.</p> <p><strong>Result: Fair Value of $17.25 (OVERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/m1vgk3ap-update-for-bausch-lomb\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, the picture could change if Pharma growth tied to dry eye treatments and premium IOL recovery in Surgical outpaces what the current share price implies.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Bausch + Lomb narrative.</a></p> <h2>Another Take on Value</h2> <p>Analysts see Bausch + Lomb as about 6.1% overvalued at $18.30 versus a $17.25 fair value, but our DCF model points the other way, with an estimate around $38.15. When one approach leans cautious and another sees a wide gap, which set of assumptions do you trust more?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/healthcare/nyse-blco/bausch-lomb/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"BLCO Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3f08b0c7-df41-4996-9f5a-57257578fcc2/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>BLCO Discounted Cash Flow as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>With mixed signals on value and growth, does the story feel convincing enough for you yet, or do you want to test it yourself against the underlying numbers and assumptions? If you want to see what the optimism is built on, take a closer look at the <a class=\"company-report-links\" data-vars-link-type=\"cta_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> and use it to shape your own view.</p> <h2>Looking for more investment ideas?</h2> <p>If you stop with just one company, you could miss opportunities that fit your style even better, so put the Simply Wall St screener to work for you.</p> <ul> <li>Zero in on quality at a discount by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that pair fundamentals with price points you may want to research next.</li> <li>Strengthen your income watchlist by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that focus on higher yielding companies to evaluate for your long term holdings.</li> <li>Spot potential early stage opportunities by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_penny_stocks\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks with strong financials</a> that still meet key financial filters before you spend time on deeper research.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Bausch + Lomb might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/healthcare/nyse-blco/bausch-lomb/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 23:56:38",
            "link": "https://simplywall.st/stocks/us/healthcare/nyse-blco/bausch-lomb/news/assessing-bausch-lomb-blco-valuation-after-strong-q4-growth",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At SUSS MicroTec (XTRA:SMHN) Valuation After Securing A New ‚Ç¨115 Million Syndicated Loan",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>SUSS MicroTec (XTRA:SMHN) has secured a new ‚Ç¨115 million syndicated loan with a five year term and two optional one year extensions. This replaces a ‚Ç¨56 million facility maturing in October 2026.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/de/semiconductors/etr-smhn/suss-microtec-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for SUSS MicroTec.</a></p> <p>The financing news lands during a period of strong momentum for SUSS MicroTec, with a 7 day share price return of 10.60%, a 90 day share price return of 61.89% and a 1 year total shareholder return of 49.22%. The ‚Ç¨55.3 share price sits against a multi year total shareholder return of 169.09% over five years.</p> <p>If this kind of move in a semiconductor equipment name has your attention, it could be a good moment to look across the sector and check out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_robotics\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 robotics and automation stocks</a> as potential next ideas.</p> <p>With the shares close to the ‚Ç¨55.75 analyst price target and an intrinsic value estimate slightly above the market price, you have to ask: is there still upside on the table, or is the market already pricing in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 17.3% Overvalued</h2> <p>The most followed narrative puts SUSS MicroTec‚Äôs fair value at ‚Ç¨47.16, which sits below the current ‚Ç¨55.30 share price and raises questions about what is already priced in.</p> <blockquote> <p><em>The analysts have a consensus price target of ‚Ç¨44.912 for SUSS MicroTec based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ‚Ç¨60.0, and the most bearish reporting a price target of just ‚Ç¨30.0.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/luosuwxp-smhn-recent-price-weakness-will-create-long-term-opportunity-despite-margin-pressures\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Want to see what holds this story together? The fair value hinges on modest revenue growth, easing margins and a richer future earnings multiple than today. Curious which assumptions really carry the weight in that model? The full narrative lays out the moving parts in detail.</p> <p><strong>Result: Fair Value of ‚Ç¨47.16 (OVERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/luosuwxp-smhn-recent-price-weakness-will-create-long-term-opportunity-despite-margin-pressures\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you still have to weigh weak order intake and margin pressure, along with softer China demand, as potential spoilers for the current fair value story.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/de/semiconductors/etr-smhn/suss-microtec-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this SUSS MicroTec narrative.</a></p> <h2>Another Angle On Valuation</h2> <p>Earlier, the fair value narrative suggested SUSS MicroTec looks 17.3% overvalued at ‚Ç¨55.30 versus a ‚Ç¨47.16 estimate. Yet on simple earnings terms, the shares trade on a P/E of 18.7x, well below the European semiconductor average of 44.1x, a peer average of 24.2x and a fair ratio of 27x. If the market moves closer to that fair ratio, the current price may still appear stretched, but there is also the possibility that the valuation gap could narrow over time.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/de/semiconductors/etr-smhn/suss-microtec-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/de/semiconductors/etr-smhn/suss-microtec-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"XTRA:SMHN P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/96a2bd95-4b4d-42bf-91fe-35db51386c57/chart/pe-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>XTRA:SMHN P/E Ratio as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>The story so far mixes optimism with real question marks, so it is worth looking at the numbers yourself and moving quickly to form your own view, especially with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/de/semiconductors/etr-smhn/suss-microtec-shares\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 1 important warning sign</a> highlighting what investors see on both sides.</p> <h2>Looking for more investment ideas?</h2> <p>If this update has sharpened your focus, do not stop at one name. Use the screener to line up a watchlist of candidates that truly fit your style.</p> <ul> <li>Scan for quality at a discount by reviewing our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">220 high quality undervalued stocks</a> that pair fundamentals with prices that some investors may find appealing.</li> <li>Prioritise resilience by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/global\" rel=\"noopener noreferrer\" target=\"_blank\">325 resilient stocks with low risk scores</a>, where companies show lower risk scores that could suit a more cautious approach.</li> <li>Hunt for lesser known opportunities with the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/global\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 566 high quality undiscovered gems</a>, a set of under the radar names that many investors may be overlooking.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 23:51:34",
            "link": "https://simplywall.st/stocks/de/semiconductors/etr-smhn/suss-microtec-shares/news/a-look-at-suss-microtec-xtrasmhn-valuation-after-securing-a",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}